Business Context and Reporting Period
This Form 8-K, dated February 17, 2021, reports that Alpha Healthcare Acquisition Corp. (AHAC) entered into a definitive Business Combination Agreement with Humacyte, Inc. Upon closing, AHAC will merge with Humacyte, with Humacyte surviving as a wholly-owned subsidiary. The combined entity is anticipated to be renamed "Humacyte, Inc." and will trade on The Nasdaq Stock Market.
Key Financial Metrics and Transaction Structure
- Implied Equity Value: The transaction values Humacyte at $800,000,000 based on the issuance of AHAC Class A Common Stock.
- PIPE Investment: AHAC secured commitments from investors to purchase 17,500,000 shares of Class A Common Stock at $10.00 per share, totaling $175,000,000 in gross proceeds.
- Contingent Value Rights (Earn-outs): Humacyte stockholders may receive up to 15,000,000 additional shares of Class A Common Stock based on post-closing trading performance:
- 7,500,000 shares if the 20-day VWAP exceeds $15.00 within a 30-day period.
- 7,500,000 shares if the 20-day VWAP exceeds $20.00 within a 30-day period.
- Debt and Liquidity: The filing does not provide specific current debt levels, cash balances, or liquidity metrics for either entity. It notes a closing condition requiring the combined company to have net tangible assets of at least $5,000,001.
Material Changes and Conditions
The primary material change is the execution of the merger agreement, transitioning AHAC from a SPAC to a combined operating company. The transaction is subject to several material conditions, including:
- Approval by stockholders of both AHAC and Humacyte.
- Effectiveness of the Form S-4 Registration Statement.
- Expiration of the Hart-Scott-Rodino Antitrust waiting period.
- Approval of the listing of Class A Common Stock on Nasdaq.
- Absence of a Material Adverse Effect on either party.
Outlook, Risks, and Management Commentary
Outlook and Agreements: The transaction includes a Sponsor Support Agreement and a Humacyte Support Agreement to secure necessary voting approvals. An Investor Rights Agreement will impose a one-year lock-up period on certain stockholders, with an early release provision if the stock price exceeds $15.00 for 20 trading days within 30 days post-closing.
Risks and Contingencies: The filing highlights significant risks, including the failure to obtain stockholder approval, regulatory hurdles, the impact of the COVID-19 pandemic on Humacyte's business, and the uncertainty of clinical trial outcomes for Humacyte's product candidates. The agreement may be terminated if the closing does not occur by August 31, 2021, or if specific breaches or regulatory prohibitions arise.
Investor Verification Checklist
- Verify the final terms and risk factors in the upcoming Form S-4 Registration Statement and Proxy Statement/Prospectus.
- Confirm the status of stockholder approvals for both AHAC and Humacyte.
- Monitor the effectiveness of the Form S-4 Registration Statement with the SEC.
- Assess the impact of the $175 million PIPE investment on the combined company's cash runway.
- Review the specific clinical development timelines and regulatory pathways for Humacyte's product candidates as detailed in the investor presentation.